Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Equity Brief: Ratings Changes for December 4th: INFY, IPI, ISRG, JAKK, KRC, LVS, MDVN, MGM


Print article Print article
Copyright © Thomson Reuters 2012. All rights reserved.
2012-12-04 16:17:57 -

A number of stocks were upgraded and downgraded by equities research analysts
today, as reported by Analyst Ratings Network ( bit.ly/equitybriefdaily)
and Equity Brief:

Cowen downgraded shares of Infosys Technologies Ltd (INFY) from an outperform
rating to a neutral rating.

BGC Financial initiated coverage on shares of Intrepid Potash, Inc. (IPI). They
issued a hold rating on the stock.

Cantor Fitzgerald raised its price target on shares of Intuitive Surgical, Inc.
(ISRG) from $475.00 to $525.00. They have a hold rating on the stock.

Zacks upgraded shares of JAKKS Pacific, Inc. (JAKK) from an underperform rating
to a neutral rating. Zacks now has a $13.00 price target on the stock. Zacks'
analyst wrote, "Jakks Pacific cut its fiscal guidance prior to the third-quarter
earnings owing to a tough retail environment. Additionally, decelerating
margins, 
top- and bottom-line miss in the third quarter of 2012, unfavorable product mix and wage inflation in China add further worry. The uncertainty around the looming fiscal cliff in the U.S. along with global economic turmoil due to the Eurozone crisis will likely keep consumers preoccupied and less inclined towards entertainment activities. However, with strong product launches, possible acquisitions, strategic partnerships, resolution of litigation and finances, Jakks Pacific is well poised for long-term growth. Also, we believe, much of the bearish thesis is reflected at the current price. The ongoing fourth quarter is also seasonally stronger for the retailers due to holiday season. Hence, we upgrade the recommendation from Underperform to Neutral." ISI Group upgraded shares of Kilroy Realty Co. (KRC) from a neutral rating to a buy rating. ISI Group now has a $51.00 price target on the stock, up previously from $49.00. Craig Hallum initiated coverage on shares of Las Vegas Sands Corp. (LVS). They issued a buy rating on the stock. Barclays Capital initiated coverage on shares of Medivation Inc (MDVN). They issued an equal weight rating on the stock. Craig Hallum initiated coverage on shares of MGM Resorts (MGM). They issued a hold rating on the stock. Brinson Patrick initiated coverage on shares of MannKind Co. (MNKD). They issued an outperform rating on the stock and set a $6.00 price target. They wrote, "MannKind Corporation's rapid-acting insulin, Afrezza, is currently in two Phase 3 pivotal trials with their handheld drug delivery device called Dreamboat. We believe the two Complete Response letters they received with their previous device has created a buying opportunity for investors today. Following a completion of a financing that carries them through 2013, we recommend investors begin accumulating MNKD shares." Stay on top of analysts' coverage with Analyst Ratings Network's free daily email newsletter that provides a concise list of analysts' upgrades, downgrades and initiations. Register at bit.ly/equitybriefdaily Content and Media Contact: newseditor@equitybrief.net This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Equity Brief via Thomson Reuters ONE [HUG#1662508]


Press Information:




Contact Person:


Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com